PHAT
NASDAQ HealthcarePhathom Pharmaceuticals, Inc. - Common Stock
Biotechnology
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
�� 市场数据
| 价格 | $13.19 |
|---|---|
| 成交量 | 904,632 |
| 市值 | 1.05B |
| 贝塔系数 | 0.610 |
| RSI（14日） | 89.9 超买 |
| 200日均线 | $12.41 |
| 50日均线 | $11.61 |
| 52周最高 | $18.31 |
| 52周最低 | $2.21 |
| Forward P/E | 8.54 |
| Price / Book | -2.15 |
🎯 投资策略评分
PHAT 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (93/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (12/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 PHAT in your text
粘贴任何文章、记录或帖子 — 工具将提取 PHAT 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.